Established in 2017, Smithfield Bioscience is a new strategic division within Smithfield Foods which leverages byproducts from the meat production process for the development of pharmaceuticals, nutraceuticals, and medical device solutions. Smithfield Bioscience has recently joined as a proud member of ARMI | BioFabUSA.
Smithfield Foods is a $15 billion global food company and the world's largest pork processor and hog producer. In the United States, the company is also the leader in numerous packaged meats categories with many popular brands and is committed to providing good food in a responsible way and maintains robust animal care, community involvement, employee safety, environmental and food safety and quality programs.
Their newest division, Smithfield Bioscience currently leads the protein industry as the first to enter the pharmaceutical, nutraceutical, and medical space, and works with multiple academic institutions on the research and development of regenerative therapies that are porcine based. This division is confident that they can support the ARMI ecosystem through the entire supply chain.
"Smithfield is a longstanding leader in sustainability and renewables with a broad geographic presence and strong manufacturing expertise," said Courtney Stanton, vice president of Smithfield Bioscience. "With these capabilities, our vertical integration and a reputation for transparency and quality, Smithfield Bioscience is well-positioned to help the U.S. medical and pharmaceutical industry achieve significant, scalable developments in biologics."
Today, Smithfield sells byproducts to pharmaceutical and nutraceutical companies who use these materials to develop drugs that treat a range of issues, from indigestion, to hypothyroidism, to deep vein thrombosis.
Smithfield Bioscience will expand upon these efforts by exploring new methods and technologies for addressing concerns such as tissue regeneration and the availability of viable human organs for transplantation. These types of cutting-edge initiatives will support a range of biotechnology solutions in areas of human therapeutics, tissue fabrication, and regenerative medicine. The division has quickly expanded from three to 30 employees to support the responsible and transparent pursuit of these science-based endeavors,
One of the first projects in partnership with the Advanced Regenerative Manufacturing Institute (ARMI) consortium is focused on technologies that will enable the repair and replacement of human tissue of soldiers injured in combat. This is especially important to Smithfield with their Operation 4000! initiative to employ 4,000 military veterans in the U.S. by 2020. With this target in mind, Smithfield Bioscience is focused on assisting and employing our military members who are returning to civilian life and workforce.
For more information contact: SmithfieldBioscience@Smithfield.com